Acumen pharmaceuticals presents innovative trial screening advancements utilizing ptau217 assay in phase 2 study of sabirnetug for early alzheimer's disease at the 17th annual clinical trials on alzheimer's disease conference

Newton, mass., oct. 31, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today presented updated data on a validated research-use plasma ptau217 assay to screen potential participants in the ongoing phase 2 altitude-ad clinical trial of sabirnetug, at the 17th annual clinical trials on alzheimer's disease (ctad) conference. the study found that this enrichment screening approach is resulting in a higher proportion of participants who meet the amyloid pet or csf-based inclusion criteria compared to acumen's phase 1 intercept-ad trial, which did not use this approach. furthermore, the enrichment approach is resulting in a more efficient participant selection process that reduces unnecessary amyloid pet scans or lumbar puncture (lp) procedures among people who are not eligible to continue in screening.
ABOS Ratings Summary
ABOS Quant Ranking